ACUT (Accustem Sciences) Moat Score: 2/10 (As of Jul. 11, 2026)


ACUT Accustem Sciences Inc ACUT
27 GF Score
Price $0.19
! 1 Warning Sign
View Full Analysis

What is Accustem Sciences Moat Score?

Accustem Sciences ACUT +21.61% 27 Moat Score is 2 as of Jul. 11, 2026. GuruFocus rates ACUT with a GF Score™ of 27/100. The stock has 1 warning sign investors should review. Among 1,395 Biotechnology companies, Accustem Sciences ranks better than 58.35% on this metric.

Accustem Sciences has the Moat Score of 2, which implies that the company might have No Moat - Very weak/transient advantages.

Accustem Sciences has No Moat: Accustem Sciences Inc lacks significant market leadership, network effects, or strong brand strength. The company does not exhibit durable cost advantages or significant regulatory barriers. Its intellectual property and innovation capabilities are not sufficiently impactful to establish a competitive edge.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Accustem Sciences might have No Moat - Very weak/transient advantages.

Accustem Sciences  (OTCPK:ACUT) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Accustem Sciences Moat Score Related Terms

ACUT vs DCOY, BIXT, SPRC: Moat Score Comparison

For the Biotechnology subindustry, Accustem Sciences's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Accustem Sciences Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Accustem Sciences's Moat Score distribution charts can be found below:

* The bar in red indicates where Accustem Sciences's Moat Score falls into.


ACUT
27GF Score
Accustem Sciences Inc ACUT
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 2 mean?
Accustem Sciences (ACUT) has a Moat Score of 2 as of Jul. 11, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Accustem Sciences ranks #581 out of 1395 companies in the Biotechnology industry, placing it in the top 41.6%.
Is Accustem Sciences' Moat Score too high?
Accustem Sciences' current Moat Score is 2. The Biotechnology industry median Moat Score is 2.00. Accustem Sciences' value of 2 is 0% at this industry median. Based on the distribution chart, Accustem Sciences ranks #581 out of 1395 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Accustem Sciences has a GF Score™ of 27/100, reflecting its overall financial health beyond just this single metric.
How does Accustem Sciences' Moat Score compare to DCOY and BIXT?
According to the Biotechnology industry distribution chart, Accustem Sciences ranks #581 out of 1395 companies for Moat Score. This puts Accustem Sciences in the upper half of its industry. The industry median Moat Score is 2.00. Accustem Sciences' value of 2 is 0% at this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,395 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Accustem Sciences's current Moat Score of 2 is 0% at the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Accustem Sciences's current Moat Score is 2. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Accustem Sciences stock overvalued right now?
Accustem Sciences (ACUT) has a current Moat Score of 2. The current Moat Score is 2 and 0% at the Biotechnology industry median of 2.00. Accustem Sciences' overall GF Score™ is 27/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Accustem Sciences (ACUT), the current Moat Score is 2 as of Jul. 11, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Accustem Sciences Business Description

Address 420 Lexington Avenue, Suite 1402, New York, NY, USA, 10001
Accustem Sciences Inc is a clinical stage diagnostics company dedicated to improving quality of life and outcomes for the millions of people who are diagnosed with cancer each year. The company's product, StemPrintER, is a genomic platform for predicting distant recurrence risk in luminal, ER+/HER2-negative breast cancer patients. Additionally, It offers ancillary commodity testing to provide further insights. Validated in various retrospective cohorts, StemPrintER shows promise for oncology clinics. Revenue is generated through product commercialization and testing services.
27GF Score

Get the complete analysis for ACUT

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price